Entrada Therapeutics Reports Third Quarter 2024 Financial Results – Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit global regulatory filings for planned Phase 2 clinical trials for both ENTR-601-44 and ENTR-601-45 in Q4 2024 – – Vertex announced the completion of the single ascending dose (SAD) and the initiation of the multiple ascending dose (MAD) portions ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinicalstage biopharmaceutical company aiming to transform the l ...

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 138.46%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced earnings of $0.68, delivering a surprise of 278.95%. Over the last four quarters, the ...

Entrada Therapeutics, Inc. (TRDA) closed the last trading session at $16.17, gaining 14.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.33 indicates a 25.7% upside potential. However, an impressive consensus price target is not the only factor that indicates a potential upside in TRDA. This view is strengthened by the agreement among analysts that the company will report bet ...

Entrada Therapeutics, Inc. (TRDA) shares rallied 10.4% in the last trading session to close at $17.37. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.9% loss over the past four weeks. Last month, the company announced positive preliminary data from its phase I ENTR-601-44-101 study, which evaluated its lead pipeline candidate, ENTR-601-44, as a potential treatment for Duchenne Muscular Dystrophy. Treatment ...

BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a clinicalstage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that it has entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stoc ...

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding the expected closing of the offering and Entrada's anticipated use of the net proceeds from the offering constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate ...

– ENTR-601-44 demonstrated significant plasma concentration, muscle concentration and exon skipping, at levels that suggest the potential for a clinically meaningful starting dose in planned upcoming patient trials – "We are excited to present the first clinical data from our Duchenne franchise, led by ENTR-601-44. ENTR601-44 was well tolerated in healthy volunteers and we are pleased to see significant plasma concentration, muscle concentration and exon skipping. We achieved the goals of the ENTR-601-44-10 ...

Shares of Entrada Therapeutics, Inc. (TRDA) have gained 17% over the past four weeks to close the last trading session at $15.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21 indicates a potential upside of 37.1%. The average comprises three short-term price targets ranging from a low of $18 to a high of $25, with a standard deviation of $3.61. While the lowest estimate i ...